Do you need help to ease the Wellbutrin Withdrawal symptoms that cause anxiety, insomnia, and mood changes? The Royal College of Psychiatrists have warned that coming off antidepressant can cause symptoms lasting for months and that doses should be gradually lowered over months. Do you want guidance throughout a slow Wellbutrin Taper with information on herbs, over-the-counter and vitamins that can interact with Wellbutrin? Our nonprofit has been helping people safely come off Wellbutrin for 15 years and we use natural, nurtraceuticals to help ease Wellbutrin Withdrawal without any concern of interactions, yet you get the relief you need for your Wellbutrin Taper. Please do not attempt to Come off Wellbutrin alone, let our kind and professional experts help you to Get off Wellbutrin. CONTACT Us for a FREE consultation.*
Our Wellbutrin weaning program is a slow taper that allows you to Get Off of Wellbutrin under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Wellbutrin until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Wellbutrin withdrawal and support well-being.*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Wellbutrin Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; goals; and interactions. Don't Wean Wellbutrin alone, work with our Prescription Drug Experts.*
Imagine being Free of Wellbutrin Dependency
- Proven Program completed In-Home with Expert Guidance
- Learn how to taper off Wellbutrin slowly
- All-Natural Nutraceuticals to help Ease Wellbutrin Withdrawal*
- Professional information on interactions
- Free Mentoring on our 24/7 private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only
WELLBUTRIN WITHDRAWAL SUCCESS STORIES
"I have never had such mental clarity before and have such a sense of being in the NOW. I never, ever realized what a fog I was in and how confused and just out of it those meds made me. I was just letting life pass me by. Thank you from the bottom of my heart." More...
Caroline, (Wellbutrin Withdrawal Success Story)
"I am generally feeling like I have better clarity of thought, my mood is lighter and I have more energy. Thank you!" More...
Peggy, (Wellbutrin Withdrawal Success Story)
EXPERIENCE and TEAMWORK
using a Natural Approach
WELLBUTRIN HISTORY AND INFORMATION
Wellbutrin is an atypical antidepressant that acts on Norepinephrine and Dopamine and belongs to the chemical class of aminoketones that are similar in structure to amphetamines. Wellbutrin is a psychostimulant that exerts its action on Dopamine and Norepinephrine. Dopamine performs a key role in the brain system’s reward-driven learning, and Norepinephrine is crucial in the fight-or-flight response by triggering the release of glucose, increasing heart rate and blood flow to the skeletal system. While the prescribing information for Wellbutrin states a gradual taper is not necessary, 30% of patients have shown Wellbutrin withdrawal symptoms do occur that include anxiety, irritability, aggression, mania, uncontrolled movements and mania. Abruptly or rapidly stopping Wellbutrin is not recommended due to the withdrawal syndrome. A gradual taper is advised.
In 2014, a court in China (world's 2nd largest pharmaceutical market) fined GlaxoSmithKline $492 million for bribing Chinese physicians and medical facilities to use more of its products, including Wellbutrin. The court sentenced Glaxo employees to prison.
Wellbutrin was released in 1986 with dosage recommendations of 400-600mg, however a significant incidence of seizures caused the drug to be removed the same year. Wellbutrin was reintroduced in 1989 with a maximum recommended dose of 450mg/day. The FDA approved the sustained-release formulation in 1996 called Wellbutrin SR that required twice a day dosing.
In 2003 the FDA approved another sustained release formulation called Wellbutrin XL that called for once a day dosing. GlaxoSmithKline Pharmaceuticals advises that Wellubtin (Buproprion) should not be prescribed to patients with epilepsy or other conditions that lower the seizure threshold.
There is evidence of neuropsychiatric symptoms associated with Wellbutrin in patients with depression, including hallucinations, psychosis, delusions, paranoia, confusion and disturbances in concentration. These side effects are also common with stimulant medications. In addition, the prescribing information lists hypertension, sometimes severe, was observed in patients both with and without pre-existing hypertension. There have been reports of a false-positive urine test for amphetamine use in persons taking Wellbutrin.
While the prescribing information for Wellbutrin states a gradual taper is not necessary, 30% of patients have shown withdrawal symptoms do occur that include anxiety, irritability, aggression, mania, uncontrolled movements and mania. Abruptly or rapidly stopping Wellbutrin is not recommended due to the withdrawal syndrome.
WELLBUTRIN WITHDRAWAL SYMPTOMS, SIDE EFFECTS, ADVERSE REACTIONS
WELLBUTRIN WITHDRAWAL SYMPTOMS MAY INCLUDE:
drowsiness, dizziness, dry mouth, blurred vision, constipation, weight gain, or trouble urinating, myocardial infarction, arrhythmia, hypotension, hypertension, palpitation, tachycardia, coma, seizures, hallucinations; delusions, confused states; disorientation, incoordination, tremors, peripheral neuropathy, abnormal involuntary movements, tardive dyskinesia, dysarthria, disturbed concentration, anxiety, insomnia, restlessness, nightmares, drowsiness, dizziness, weakness, fatigue, headache, syndrome of inappropriate ADH secretion, tinnitus, hyperpyrexia, urinary retention, dilation of urinary tract, constipation, blurred vision, increased ocular pressure, skin rash, urticarial, edema of face and tongue, bone marrow depression, nausea, vomiting, anorexia, stomatitis; peculiar taste, diarrhea, black tongue, testicular swelling, breast enlargement – female, increased or decreased libido, impotence, elevation and lowering of blood sugar levels, alopecia, weight gain or loss, urinary frequency, increased perspiration
WELLBUTRIN SIDE EFFECTS MAY INCLUDE:
aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression
WELLBUTRIN ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: suicidal ideation, seizures, anaphylactoid reactions, coma, stroke, myocardial infarction, GI perforation, GI bleeding, bronchospasm, Tourette's syndrome, pulmonary embolism, AV block, ocular hypertension, pancreatitis, exfoliative dermatitis, SIADH, pancytopenia, rhabdomyolysis, erythema multiforme, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylactic shock, serum sickness, Stevens-Johnson syndrome, angioedema, tardive dyskinesia, akinesia, hearing loss, neonatal abstinence syndrome, serotonin syndrome
Moderate: constipation, migraine, blurred vision, sinus tachycardia, confusion, palpitations, hostility, hypertension, chest pain (unspecified), impotence (erectile dysfunction), memory impairment, hot flashes, hypotension, dysphoria, dysphagia, oral ulceration, vaginal bleeding, urinary retention, akathisia, pseudoparkinsonism, euphoria, dysarthria, psychosis, depression, peripheral vasodilation, orthostatic hypotension, jaundice, elevated hepatic enzymes, teeth grinding (bruxism), glossitis, testicular swelling, ejaculation dysfunction, dyspnea, peripheral edema, hypertonia, aphasia, neuropathic pain, EEG changes, amnesia, phlebitis, colitis, dyspareunia, dysuria, cystitis, ataxia, mania, hallucinations, myoclonia, edema, stomatitis, dystonic reaction, dyskinesia, delirium, impulse control symptoms, esophagitis, hepatitis, hyperglycemia, hypoglycemia, glycosuria, hyponatremia, leukopenia, lymphadenopathy, thrombocytopenia, anemia, myasthenia, urinary incontinence
Mild: insomnia, headache, agitation, xerostomia, weight loss, vomiting, nausea, hyperhidrosis, tremor, anorexia, weight gain, pharyngitis, rhinitis, dizziness, abdominal pain, infection, anxiety, rash, diarrhea, flatulence, myalgia, tinnitus, arthralgia, sinusitis, fatigue, increased urinary frequency, menstrual irregularity, flushing, dysgeusia, pruritus, asthenia, cough, appetite stimulation, hypersalivation, dyspepsia, libido decrease, drowsiness, irritability, diplopia, restlessness, paresthesias, dysmenorrhea, urticaria, xerosis, fever, epistaxis, urinary urgency, syncope, chills, vertigo, paranoia, emotional lability, xerophthalmia, gastroesophageal reflux, polydipsia, gingivitis, vaginal irritation, gynecomastia, acne vulgaris, photosensitivity, ecchymosis, back pain, muscle cramps, dental pain, polyuria, hyperkinesis, pallor, maculopapular rash, hirsutism, malaise, hair discoloration, drug-induced body odor, lethargy, libido increase, alopecia, influenza, nasal congestion, nocturia, mydriasis, leukocytosis
WELLBUTRIN BOXED WARNINGS: per PDR
Children, suicidal ideation
The safety and efficacy of bupropion for smoking cessation is not established in children or adolescents. Children 6 years and older with a major depressive episode or attention-deficit hyperactivity disorder (ADHD) have been studied in clinical trials of bupropion, but data regarding pediatric safety are limited. When bupropion is used for the treatment of ADHD in pediatrics, careful screening and monitoring is recommended by the American Heart Association. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events was 4% on drug and 2% for placebo; however, no suicides occurred. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavioral changes. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or behavioral changes, particularly within the first few months of starting therapy or during dose adjustments. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in any patient with depressive symptoms, whether these occur in a primary depressive episode or in association with another primary disorder such as OCD. In patients who exhibit adverse changes in symptoms, worsening of depressive symptoms, or suicidality, a decision should be made to change or discontinue treatment. If discontinuing bupropion, the medication should be tapered as rapidly as possible, but with recognition that discontinuing treatment abruptly can also cause adverse symptoms. Bupropion should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose.
WELLBUTRIN REFERENCES AND OTHER INFO
According to the FDA:
General: Agitation and Insomnia: A substantial proportion of patients treated with WELLBUTRIN experience some degree of increased restlessness, agitation, anxiety, and insomnia, especially shortly after initiation of treatment. In clinical studies, these symptoms were sometimes of sufficient magnitude to require treatment with sedative/hypnotic drugs. In approximately 2% of patients, symptoms were sufficiently severe to require discontinuation of treatment with WELLBUTRIN.
Psychosis, Confusion, and Other Neuropsychiatric Phenomena: Depressed patients treated with WELLBUTRIN have been reported to show a variety of neuropsychiatric signs and symptoms including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. Because of the uncontrolled nature of many studies, it is impossible to provide a precise estimate of the extent of risk imposed by treatment with WELLBUTRIN. In several cases, neuropsychiatric phenomena abated upon dose reduction and/or withdrawal of treatment.
Activation of Psychosis and/or Mania: Antidepressants can precipitate manic episodes in bipolar disorder patients during the depressed phase of their illness and may activate latent psychosis in other susceptible patients. WELLBUTRIN is expected to pose similar risks.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and consent throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..